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Abstract 
In this work several nanoporous titania powders have been considered as potential 
carriers for the sustained release of ibuprofen, used as model drug. The textural features 
and the physico-chemical nature of the surface carriers have been investigated by means 
of N2 physisorption measurements and FT-IR analyses. The delivery profiles have been 
collected in vitro in physiological solution at pH 7.4, maintaining the temperature at 
37°C. It has been possible to observe a close correlation between the drug release 
kinetic and the textural properties of the carriers, in particular for what concerns their 
pores dimension. The choice of the proper synthetic approach allows a high control of 
the properties of the final material and of its behaviour in the drug delivery process that 
can be controlled to a very high extent. 
Keywords: TiO2, pores dimension, drug delivery, ibuprofen 
1. Introduction 
In recent years controlled drug delivery applications have gained increasing attention 
and the rapid expansion in the advanced materials and technology has resulted in a 
remarkable progress in their development. The aim of controlled drug delivery is (i) to 
administer the requested amount of drug to the relevant sites in the human body and (ii) 
to regulate the drug delivery profile, in order to obtain the optimal therapeutic benefits 
as much as possible. The conventional metals, oxides and mixed materials used in the 
drug/medical devices are generally designed at the nano-scale level. In fact, nanoporous 
materials and coatings are characterized by large surface area and tuneable pores size; 
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moreover, their surface chemical properties can be manipulated ad hoc to suit the final 
applications. 
In particular, many efforts have been (and are) devoted to the realization of nano- 
structured materials combining controlled drug delivery properties with the features 
required by tissue engineering (i.e., design of devices that replace or act as a fraction of 
the whole biological structure). 
These studies deal with either polymeric materials and/or with inorganic oxides, such as 
nanoporous alumina, porous silicon, nanostructured ceramics and nanostructured TiO2 
[1-3]. Among these systems titanium and TiO2 materials are well known in the 
biomedical applications since the 1970s for their use as orthopaedic implants. In fact, 
titanium, titanium based alloys and TiO2 systems are among the most common implant 
materials (such as cardiovascular stents, joint replacements and dental implants) used in 
the human body because of their desirable mechanical strength, low density, excellent 
resistance to corrosion and lack of cytotoxic effects [3-5]. The addition of controlled 
drug delivery properties to the well known features of TiO2 could expand its potential 
applications in the biomedical field, and this represents a very attractive field of 
research. 
Several works concerning the use of TiO2 nanotubes as drug carriers have been 
published [6-8]; in particular, Popat et al. [9] have studied and reported the effect of 
titania nanotubes templates as sustained drug release platforms for the treatment of 
acute infections arising after orthopaedic implant surgeries. These studies evidenced 
that titania nanotemplate carriers are not only effective against the bacterial infection 
but, parallel to this, they exhibit improved osteoblast cell adhesion and growth. 
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In addition to biocompatibility, another important issue must be considered, i. e. the 
textural properties of the material. A carrier possessing high surface area, large pore 
volume and proper pore size is fundamental to ensure the loading of the support with 
the desired amount of drug, thus increasing its adsorption capacity [10]. Moreover, 
among the several factors affecting the release profile (i. e. the nature of the carrier, the 
chemical interactions between the drug and the support, etc), the pores size dimension 
hardly affects the performance of a drug delivery system, because it influences the rate 
by which the drug is released from the matrix [11]. The possibility to tune the pores size 
distribution of the support then allows a better control of the drug release profile. 
Titania nanoporous surfaces are usually prepared either using an anodization method 
[12] or by employing a block copolymer in combination with a titanium precursor 
(TiCl4) [13]. Many studies are reported on the design of nanostructured titania or 
titania-silica biomedical ceramics obtained by the sol-gel method, which is a very 
attractive technique because it allows a high control of the textural properties of the 
final products by choosing the proper synthetic conditions; this fact becomes 
particularly important for the possible use of nanostructured carriers in the drug delivery 
process. 
There are several examples of TiO2, SiO2 and TiO2/SiO2 carriers prepared by the sol-gel 
approach [14-17]. Lopez et al. [18] have investigated a sol-gel synthesized 
nanostructured TiO2 matrix with different channel size as reservoirs for the controlled 
delivery of Temozolomide, an important drug for the treatment of tumors. 
In the light of the remarkable potentialities of TiO2 in the biomedical field, in the 
present work the attention was focused on several TiO2 nanoporous matrices to sustain 
the release of ibuprofen, used as model drug. A series of commercial titania nano- 
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powders and a TiO2 sample prepared by a sol-gel method were investigated in order to 
identify the correlation among the synthetic approach, the physico-chemical properties 
and the drug delivery behaviour. 
2. 
2.1 
Experimental 
Materials 
Ethanol (Fluka), Tris Buffered Saline (0.2 M TRIS HCl; 9.0% NaCl; pH 7.5±0.1) 
(Fluka), hydrochloric acid (Fluka), titanium tetraisopropoxide Ti(OC3H7)4 (Fluka), 
Ibuprofen sodium salt (Aldrich), isopropyl alcohol (Fluka). All reagents have been used 
as received. 
2.2 Synthesis 
2.2.1 TiO2 powders 
Five matrices were selected as potential carriers: four commercial TiO2 powders (P25, 
Millennium, Mirkat, PC105) and a TiO2 matrix synthesized in our laboratory by a sol- 
gel approach as briefly described in the following. The Ti(OC3H7)4 precursor (25 mL) 
was suspended in 2-PrOH (23 mL): the proper amount (80 mL) of H2O was added 
dropwise to this suspension under vigorous stirring. The obtained sol was stirred for 90 
minutes and then aged at room temperature in static condition for 20h. The aged gel was 
dried at 80°C for 12 h and finally calcined at 300°C in flowing air. The final material 
was labelled as TiO2. 
The drug was embedded on the carriers by incipient wetness impregnation as previously 
reported in ref. [19]. In a typical synthesis, a proper amount of ibuprofen sodium salt (in 
order to obtain a concentration of 80 mg of ibuprofen/g TiO2) was dissolved in ethanol 
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and added to 1g of the titania support containing a pore volume equal to that of the 
added solution. Capillary action draws the solution into the pores. The drug/TiO2 
composite was then dried at 50°C for 12 hours to get off the volatile components within 
the solution. The obtained samples were conformed (pressure 2.5 Ton for 5 minutes) as 
capsules (diameter 1.2 cm; thickness: 0.5 cm). 
2.2.2 Delivery release (in vitro study) 
In vitro study of ibuprofen release from the supports was performed as follows. 
In a typical experiment, a capsule was soaked in a proper volume (10 mL) of a saline 
solution at pH 7.4 and maintained at 37°C. Samples of 1 mL were removed from the 
solution at predetermined times and replaced by the same volume of fresh medium. The 
drug concentration in the liquid phase was evaluated by UV spectrometry at 272 nm 
(Perkin-Elmer λ40 instrument). Calibration curve of ibuprofen was determined by 
taking absorbance vs ibuprofen concentration between 0 and 2000 ppm as reference 
parameters. The effective drug concentration in solution was calculated on the basis of 
the following equation [20]: 
where Ceff is the corrected concentration at time t, Capp is the apparent concentration at 
time t, v is the volume of sample taken and V is the total volume of the dissolution 
medium. 
In order to check the reliability of the collected data, a test was carried out in the 
conditions previously reported by taking a single sample from the dissolution medium 
at the end of the release experiment. We have obtained the same drug concentration 
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value of that calculated on the basis of the formula for a drug release test studied with 
multiple sampling. 
In order to check for reproducibility, each release test has been carried out in triplicate 
by collecting, each time, the data analysis simultaneously from two identical tablets. 
2.2.3 Characterization 
Specific surface area and pores size distribution were obtained from N2 adsorption- 
desorption isotherms at 77K (MICROMERITICS ASAP 2000 Analyser). Surface area 
was calculated by the BET equation [21], whereas the mesopores size distribution was 
determined by the BJH method [22], applied to the N2 adsorption isotherm branch. Prior 
to the adsorption experiments all the analysed samples were outgassed in vacuum at 
room temperature (RT) for 12 h. 
FTIR spectra were obtained on a BRUKER 113v spectrophotometer (2 cm-1 resolution, 
MCT detector). All materials were inspected in the form of self-supporting pellets ( 10 
mg cm-2). All samples were activated in controlled atmosphere at IR beam temperature 
(BT, namely  60°C) in quartz cells connected to a gas vacuum line, equipped with 
mechanical and turbo molecular pumps (residual pressure p<10-5 Torr). Samples have 
been treated (i.e., evacuated) only at BT from 1 up to 60 min in order to get rid of all 
physisorbed species. 
3. Results and discussion 
In order to evaluate the possibility of using a TiO2 matrix as carrier to sustain the 
release of a drug molecule and identify the key factors affecting the delivery behaviour, 
four commercial TiO2 nano-powders have been selected and tested as carriers for the 
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controlled release of ibuprofen. The matrices were chosen on the basis of their textural 
properties, i.e. surface area and pores dimension. 
The drug was introduced on the matrices by incipient wetness impregnation, an 
effective and reliable method for the preparation of porous oxide/drug composites, as 
reported in ref. [19]. 
The corresponding drug delivery profiles are reported in Figure 1. 
First of all it is possible to evidence that, at the end of the delivery experiment, both 
shape and dimensions of the tablet are unchanged. This confirms that the release process 
is due to the drug diffusion out of the tablet and not to the dissolution of the titania 
matrix. 
The four delivery profiles are quite different. For the P25 sample the release rate is very 
fast and almost all the drug embedded in the TiO2 carrier is delivered in the first 4-6 
hours. On the other hand, Mirkat and Millennium samples exhibit a very similar drug 
release profile: gradual and controlled to a high degree, but extremely slow. In fact at 
the end of the delivery experiment only a limited fraction (~ 30%) of the drug is 
released from these two matrices. Among the investigated carriers, PC105 exhibits the 
best performance: its release profile is rather controlled and most of the drug is released 
at the end of the delivery test. 
In order to explain these results, FTIR and N2 physisorption analyses were resorted to. 
All systems have been characterized by means of FTIR spectroscopy in order to obtain 
information about: (i) all surface terminations (i.e., intrinsic and/or added 
functionalities); (ii) the nature of the interaction between the TiO2 surface and the 
embedded ibuprofen. 
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Figure 2 reports the FTIR profiles collected after 1 hour evacuation at RT. The 
temperature of the thermal dehydrating treatment has been kept close to the 
physiological temperature (i.e. ~37°C), in order to avoid any decomposition/alteration 
of the drug itself. 
FTIR spectra are very similar for all the investigated systems. As for the spectra relative 
to the plain TiO2 systems (set b in each section of Figure 2), all of them exhibit the 
typical OH pattern of titania, i,e,: 
(i) a complex band located in the 3600-3700 cm-1 range which can be ascribed, on 
the basis of its spectral behaviour and of literature data [23], to the stretching 
mode (  -OH species free from hydrogen bonding interactions; 
(ii) a broad envelope, located in the 3600-3000 cm-1 range, which can be ascribed to 
the  -bonded OH groups present at the surface of the solid [24]. This 
is not surprising, as an activation in vacuo at RT can only get rid of the 
physisorbed fraction of (associated/undissociated)water molecules present at the 
surface of the various TiO2 systems; 
(iii) a complex of bands (in some cases present in an envelope, in some other ones 
singled out in components) located in the 3100-2750 cm-1 range (somehow 
superimposed to the envelope described in (ii)) and ascribable to the stretching 
modes ( CH) due to hydro-carbonaceous species present at the surface of TiO2. 
This is again not surprising, as after the calcinations step all powders were 
exposed to the laboratory atmosphere, in which contaminants, like hydrocarbons 
and CO2, are present and can readily react with the oxide surface to give rise to 
surface species [25]. This reaction is very rapid and favoured if the nature of the 
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oxide is ionic: this is the case of alumina, titania and in general of all IVB group 
metal oxides [26]; 
(iv) as for the envelope located at  < 1800 cm-1, it is mainly made up of a 
component centred at  1630 cm-1, ascribable to the HOH mode of undissociated 
water molecules. At lower , the bands can be ascribed to the spectral modes of 
surface carbonates/hydrogenocarbonates generated by the reaction of CO2 with 
the surface species of the ionic oxide [27]. 
Curves a in each set of figure 2 refer to the spectra relative to the various model TiO2 
impregnated with Ibuprofen. It is possible to observe that in all cases the typical OH 
pattern of the titania matrix above described is strongly affected by the presence of the 
bioactive molecule. In fact, the envelope of bands ascribable to the “free” Ti-OH 
species (  in the 3620-3700 cm-1 range) is totally absent in the case of all the 
titania+ibuprofen samples. Moreover, it is worth noting that the presence of additional 
bands on the profile of the titania/drug composite is due to the presence of ibuprofen. In 
fact, in the high  region (2750–3100 cm-1), new sharp bands appear: their spectral 
behaviour allows to assign them to either C-H stretching modes ( ~2800-3100 cm-1) of 
all CH-containing species of either aliphatic or aromatic nature or to the N-H stretching 
vibration modes ( ~3000-3400 cm-1) present in the ibuprofen molecule. At low 
frequency ( <1800 cm 1) intense and broad bands are also present: these represent 
either the spectral bending ( C-H, N-H) counterparts of the above-described stretching 
modes of all CH- and NH-containing species or the CO (~1695 cm-1) of the carboxylic 
residue present in the drug. 
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All these features confirm the presence of the bioactive molecule on the matrices and its 
interaction with the titania surface is likely to take place by hydrogen bond. This is 
confirmed by the differential curves (a)-(b) reported in the FTIR patterns, as signals 
relative to species that disappear (i.e. OH species) upon drug loading are pointing down, 
whereas bands relative to species that appear ( CH,NH and CH,NH) after ibuprofen loading 
are pointing up. 
These results are significant but they cannot justify the very different delivery behaviour 
exhibited by the various samples. In order to shed some light on these differences, N2 
physisorption analyses were carried out. The adsorption/desorption isotherms and the 
pores size distributions of the TiO2/ibuprofen pressed samples are reported in figure 3 
and figure 4, respectively; surface area, pore volume and pores diameter values of both 
ibuprofen-free and unpressed TiO2 samples and drug loaded and pressed samples are 
listed in Table 1. 
In all cases, it is possible to observe a significant contraction of BET surface area and 
pore volume values and a slight reduction of the pores diameter in all the drug loaded 
and pressed samples compared to the plain TiO2 systems. 
Both effects can be plausibly attributed to the presence of the drug into the pores and 
this fact confirms the successful adsorption of the active molecule inside the porous 
network; another contribution could derive from the partial collapse of the structure, as 
a consequence of the tableting action. In any case, in all pressed samples the original 
texture of the carriers is preserved to a high degree, as the isotherms shapes are very 
similar for both the pressed and un-pressed systems. This is an important result, which 
indicates (i) the reliability of the synthetic method, but also (ii) the mechanical stability 
of the investigated TiO2 systems. 
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Mirkat/Ibu and Millennium/Ibu samples exhibit a IV type adsorption-desorption 
isotherm which contains an H3 hysteresis loop (IUPAC definition) [28]. The hysteresis 
loop is extended in a wide range of relative pressure (from 0.4 to 0.9), suggesting a 
broad distribution of the pores dimension. In fact, these distributions are characterized, 
for both samples, by a bi-modal distribution with a large fraction of small pores 
(centered around 3.5 nm) and another fraction of bigger pores (between 10 and 70 nm). 
On the contrary, the isotherm relative to the P25/Ibu sample is that typical of a material 
characterized by large pores, as confirmed by the BJH distribution curve (see Figure 4): 
the small value of surface area (36 m2/g) is in good agreement with these evidences. The 
isotherm of PC105/Ibu is similar in shape to that of the P25/Ibu sample, but the total 
volume adsorbed is higher and the hysteresis loop starts at lower pressure according to 
the presence of smaller pores [29]. It can be supposed that these significant differences 
in the textural properties exhibited by the different titania systems strongly affect their 
behaviour in the drug delivery process and provide a key role on directing the drug 
kinetic release. 
A standard controlled drug release mechanism involves: (i) diffusion of the drug 
through the carrier matrix; (ii) carrier matrix erosion; (iii) combined erosion/diffusion 
process; (iv) interaction between matrix and drug molecules. In the case of the TiO2 
carriers the drug delivery process is mainly controlled by diffusion: the drug dissolves 
in the release medium and then diffuses from the matrix into the solution along the 
solvent-filled porous channels. The comparison between the drug delivery profiles and 
the pores size distributions (see Figure 4) suggests a close correlation between pores 
dimension and drug diffusion process. In the case of Mirkat/Ibu and Millennium/Ibu 
systems, which are characterized by both a very similar bi-modal pores size distribution 
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and a definite number of pores with relatively small dimensions (2±5 nm), the ibuprofen 
release out of the porous matrix is well controlled; but unfortunately a lot of the drug 
keeps trapped into these smaller pores (d~2 nm). On the other hand, the large pores of 
P25/Ibu sample are absolutely detrimental for the drug release kinetic, which is too fast 
and uncontrolled. A good compromise is achieved only in the case of the PC105/Ibu 
system that possesses pores of suitable dimensions (centred on a relatively extended 
range of size, 6-25 nm): this feature allows a fair control of the delivery process and 
ensures the release of almost all the loaded drug. 
N2 physisorption analyses were carried out on the samples Millennium/Ibu and 
PC105/Ibu at the end of the release process, in order to verify what happens to the 
systems after the desorption of the drug. We chose these two samples because their 
performance in the release process is quite different: the PC105/Ibu sample releases 
most of the loaded ibuprofen, while the Millennium matrix retains a great amount of the 
drug. 
The shape of the isotherms of both samples remained unaltered, thus deducing that their 
structural integrity was preserved, but an increase of the surface area (compared to that 
of the samples before the release tests) was observed. The PC105/Ibu sample has a final 
surface area of 68 m2/g, while that of the Millennium/Ibu sample is 137 m2/g; the 
increase is then of 21% and 12% respectively. These results confirm that part of the 
drug loaded in the matrices desorbed setting the pores free. It is also possible to note 
that a strict correlation between the amount of ibuprofen released from the matrix and 
the increase of the surface area exists: in the case of the PC105 sample, which released 
~90% of the ibuprofen loaded, the increase of the surface area is twice as that of the 
Millennium sample, which retains a lower amount (only ~50%) of the drug. 
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In order to further verify the role of the TiO2 textural properties on the drug delivery 
process and to obtain a release profile controlled to a high extent, a TiO2 matrix was 
synthesized employing a sol-gel approach (see section 2.2.1). The main target was the 
synthesis of a final material (TiO2/Ibu) characterized by both high surface area and 
pores with dimension between that of Mirkat and Millennium systems (which exhibited 
slow and partial drug release) and that of PC105 sample (which on the contrary 
exhibited a drug release almost complete but quite fast). The first step of the study was 
then the check of both surface and textural properties of this system by means of FTIR 
spectroscopy and N2 physisorption analysis, respectively. 
Figure 5 reports the FTIR profiles collected after 1 hour evacuation at BT, i.e., in the 
same conditions experienced by all the other samples. It is again possible to evidence 
that the typical OH pattern of the titania matrix is strongly affected by the presence of 
the bioactive molecule. In fact, the band ascribable to the “free” Ti-OH species ( ~ 
3655 cm-1) [23] is totally absent in the case of ibuprofen-loaded samples. Moreover, the 
presence of ibuprofen is witnessed, as also reported in case of the commercial 
TiO2+ibuprofen samples (see figure 2), by the spectral components located in: 
- the 2750–3100 cm-1 range where sharp bands appear. On the basis of their 
spectral behaviour, they are assigned to (i) C-H stretching modes ( ~2800-3100 
cm-1) due to all CH-containing species of either aliphatic or aromatic nature and 
(ii) or the N-H stretching vibration modes ( ~3000-3400 cm-1) present in the drug 
molecule; 
- At low frequency ( <1800 cm 1) intense and broad bands are also present, 
representing the same features reported in the case of the commercial drug loaded 
titania samples. 
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The isotherms and the pores size distributions of the as-synthesized TiO2 and of the 
ibuprofen loaded and pressed carrier are reported in figure 6. 
The adsorption-desorption isotherms are typical of mesoporous systems with relatively 
high surface area (189 and 146 m2/g respectively, for plain TiO2 and TiO2/Ibu) and 
unimodal pores size distribution. As expected, the addition of the drug and the tableting 
action lead to a decrease of both surface area and pores volume, even if the original 
texture of the TiO2 sample is preserved, as confirmed by the unchanged shape of the 
isotherm. In figure 6(b) it can be observed that pores size (3-7 nm) of the TiO2/Ibu 
sample is effectively consistent with what expected in the case of the different 
commercial samples (see Figure 4): the TiO2/Ibu system possesses pores exhibiting 
diameters with dimensions between those of the PC105/Ibu (6-25 nm) and of the 
Millennium/Ibu samples (3-4/15-60 nm). This result confirms that the sol-gel approach 
allows to control to a high degree the textural properties of the final material. In 
particular, we observed that through the optimization of the synthesis parameters (Ti 
precursor:water ratio, solvent amount, rate of water addition, aging modality) a 
modulation of the pores size distribution can be achieved. 
Figure 7(a) reports the drug release from the TiO2/Ibu sample. The delivery profile is 
gradual and well controlled: at the end of the experiment ~ 67% of the total ibuprofen 
initially loaded has been released from the tablet (this value is definitely higher than that 
obtained in the case of the Millennium/Ibu and Mirkat/Ibu samples). Despite the partial 
drug release, the behaviour of this sample can be considered suitable for the realization 
of a controlled drug delivery system. This result is very significant as confirms the close 
correlation between the pores dimension of the carriers and the drug release process. 
This feature affects to a high extent the release trend, that is slower and more controlled 
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than that exhibited by the PC105/Ibu system, with a final released drug amount higher 
than that obtained for the Millennium/Ibu sample. An important role in directing the 
drug delivery process is probably played by the pores dimension of the TiO2/Ibu 
system, and also by the unimodal nature of its pores distribution. This kind of 
distribution favours a more controlled and uniform drug release than that exhibited by a 
bi-modal distribution. 
4. Conclusions 
In this work we have studied a series of nanoporous titania systems as possible carriers 
to sustain the release of ibuprofen, a well known anti-inflammatory drug. 
By a sol-gel approach it is possible to modulate the physico-chemical properties of the 
matrix as a function of the dimension of the drug, thus controlling the rate of its release. 
In particular, we have observed a close correlation between the pores dimension of the 
matrix and the release rate of the embedded drug: it is then possible to design a drug 
delivery device as a function of the final application (i. e. dimension of the drug, 
therapeutic action duration, …). 
A further improvement here reported could be then gained by the synthesis of a matrix 
possessing pores dimension slightly shifted towards higher values, in order to achieve 
the total release of the embedded drug, as well as a gradual and well controlled delivery 
profile. 
This work shows the possibility of combining the well known biocompatibility of TiO2 
with drug delivery properties, thus increasing the number of potential applications of 
this inorganic material in the biomedical field. 
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Table 1 
Sample 
Ibuprofen 
 amount 
(mg) 
 BET 
surface 
 area 
(m2/g) 
52 
36 
84 
56 
329 
131 
339 
121 
189 
146 
 Total 
 Pore 
Volume 
(mL/g) 
0.3 
0.2 
0.4 
0.2 
0.5 
0.3 
0.5 
0.3 
0.3 
0.2 
  Pore 
diameter 
  (nm) 
>10 
15-40 
7-40 
6-25 
4-5/15-70* 
3-4/10-70* 
4-5/5-45* 
3-4/15-60* 
2.5-7 
3-7 
P25 
P25/Ibu 
PC105 
PC105/Ibu 
Mirkat 
Mirkat/Ibu 
Millennium 
Millennium/Ibu 
TiO2 
TiO2/Ibu 
0 
80 
0 
80 
0 
80 
0 
80 
0 
80 
*bi-modal pores size distribution 
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Figure captions 
Figure 1. a) Ibuprofen (%) release as a function of the immersion time in the release 
medium (n=3, mean±sd); b) release profiles in the first 360 min of analysis. 
Figure 2. Absorbance FTIR spectra in the 4000-1250 cm-1 range for the plain (b) and 
ibuprofen loaded (a) TiO2 matrices. (a)-(b) Differential curves obtained subtracting the 
spectrum of the plain TiO2 material to the spectrum of the drug loaded corresponding 
system. 
Figure 3. N2 adsorption/desorption isotherms of the drug loaded and pressed TiO2 
commercial samples. 
Figure 4. Molecular model of ibuprofen (a) and BJH pores size distribution of the 
ibuprofen loaded TiO2 commercial samples (b). 
Figure 5. Absorbance FTIR spectra in the 4000-1250 cm-1 range for the plain (b) and 
ibuprofen loaded (a) TiO2 home-made matrix. (a)-(b) Differential curves obtained 
subtracting the spectrum of the plain TiO2 material to the spectrum of the drug loaded 
corresponding system. 
Figure 6. N2 adsorption/desorption isotherms (a) and BJH pores size distributions (b) of 
the plain TiO2 home-made system and of the drug loaded and pressed sample. 
Figure 7. Drug delivery profiles (a) and BJH pores size distribution (b) of PC105/Ibu, 
TiO2/Ibu and Millennium/Ibu samples. 
Table captions 
Table 1. Surface area, pore volume and pores diameter values of the ibuprofen-free and 
unpressed TiO2 samples and of the drug loaded and pressed samples 
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Figure 2 
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Figure 3 
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Figure 4 
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Figure 5 
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Figure 6 
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Figure 7 
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